[Translated article] Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain
CONCLUSIONS: The implementation and development of the MAPEX initiatives has had a positive impact on the evolution in all healthcare areas of pharmaceutical care for outpatients. The situation survey makes it possible to identify by regions the significant points for improvement, as well as those areas to be developed through strengthening and corrective actions. The expansion of the project in the coming years will mean progress toward excellence in care and in the improvement of health results.PMID:38151407 | DOI:10.1016/j.farma.2023.11.001 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 27, 2023 Category: Drugs & Pharmacology Authors: Esther Vicente-Escrig Pilar Taberner Bonastre Olatz Ibarra Barrueta Manuel Murillo Izquierdo Cecilia M Fern ández-Llamazares Ram ón Morillo-Verdugo Source Type: research
[Translated article] Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain
CONCLUSIONS: The implementation and development of the MAPEX initiatives has had a positive impact on the evolution in all healthcare areas of pharmaceutical care for outpatients. The situation survey makes it possible to identify by regions the significant points for improvement, as well as those areas to be developed through strengthening and corrective actions. The expansion of the project in the coming years will mean progress toward excellence in care and in the improvement of health results.PMID:38151407 | DOI:10.1016/j.farma.2023.11.001 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 27, 2023 Category: Drugs & Pharmacology Authors: Esther Vicente-Escrig Pilar Taberner Bonastre Olatz Ibarra Barrueta Manuel Murillo Izquierdo Cecilia M Fern ández-Llamazares Ram ón Morillo-Verdugo Source Type: research
[Translated article] Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain
CONCLUSIONS: The implementation and development of the MAPEX initiatives has had a positive impact on the evolution in all healthcare areas of pharmaceutical care for outpatients. The situation survey makes it possible to identify by regions the significant points for improvement, as well as those areas to be developed through strengthening and corrective actions. The expansion of the project in the coming years will mean progress toward excellence in care and in the improvement of health results.PMID:38151407 | DOI:10.1016/j.farma.2023.11.001 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 27, 2023 Category: Drugs & Pharmacology Authors: Esther Vicente-Escrig Pilar Taberner Bonastre Olatz Ibarra Barrueta Manuel Murillo Izquierdo Cecilia M Fern ández-Llamazares Ram ón Morillo-Verdugo Source Type: research
[Translated article] Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain
CONCLUSIONS: The implementation and development of the MAPEX initiatives has had a positive impact on the evolution in all healthcare areas of pharmaceutical care for outpatients. The situation survey makes it possible to identify by regions the significant points for improvement, as well as those areas to be developed through strengthening and corrective actions. The expansion of the project in the coming years will mean progress toward excellence in care and in the improvement of health results.PMID:38151407 | DOI:10.1016/j.farma.2023.11.001 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 27, 2023 Category: Drugs & Pharmacology Authors: Esther Vicente-Escrig Pilar Taberner Bonastre Olatz Ibarra Barrueta Manuel Murillo Izquierdo Cecilia M Fern ández-Llamazares Ram ón Morillo-Verdugo Source Type: research
[Translated article] Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain
CONCLUSIONS: The implementation and development of the MAPEX initiatives has had a positive impact on the evolution in all healthcare areas of pharmaceutical care for outpatients. The situation survey makes it possible to identify by regions the significant points for improvement, as well as those areas to be developed through strengthening and corrective actions. The expansion of the project in the coming years will mean progress toward excellence in care and in the improvement of health results.PMID:38151407 | DOI:10.1016/j.farma.2023.11.001 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 27, 2023 Category: Drugs & Pharmacology Authors: Esther Vicente-Escrig Pilar Taberner Bonastre Olatz Ibarra Barrueta Manuel Murillo Izquierdo Cecilia M Fern ández-Llamazares Ram ón Morillo-Verdugo Source Type: research
[Translated article] Analysis 2016-2021 of the development of the MAPEX outpatient pharmaceutical care Project by Regions in Spain
CONCLUSIONS: The implementation and development of the MAPEX initiatives has had a positive impact on the evolution in all healthcare areas of pharmaceutical care for outpatients. The situation survey makes it possible to identify by regions the significant points for improvement, as well as those areas to be developed through strengthening and corrective actions. The expansion of the project in the coming years will mean progress toward excellence in care and in the improvement of health results.PMID:38151407 | DOI:10.1016/j.farma.2023.11.001 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 27, 2023 Category: Drugs & Pharmacology Authors: Esther Vicente-Escrig Pilar Taberner Bonastre Olatz Ibarra Barrueta Manuel Murillo Izquierdo Cecilia M Fern ández-Llamazares Ram ón Morillo-Verdugo Source Type: research
[Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol
CONCLUSION: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analysed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making.PMID:38148255 | DOI:10.1016/j.farma.2023.11.004 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 26, 2023 Category: Drugs & Pharmacology Authors: Andr és Navarro Ruiz Fernando Toledo Alberola Susana Aceituno Grupo ARCODERM Source Type: research
[Translated article] Design of a panel of indicators for antibiotic stewardship programs in the Emergency Department
CONCLUSIONS: The experts agreed on a panel of ASP Indicators adapted to the emergency services prioritised by level of relevance. This is as a helpful tool for the development of these programs and will contribute to monitoring the appropriateness of the use of antimicrobials in these units.PMID:38148256 | DOI:10.1016/j.farma.2023.11.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 26, 2023 Category: Drugs & Pharmacology Authors: Jes ús Ruiz-Ramos Mar ía Rosario Santolaya-Perrín Juan Gonz ález-Del-Castillo Francisco Javier Candel Alejandro Mart ín-Quirós Joaqu ín López-Contreras-González Agust ín Julián-Jiménez Ana Su árez-Lledó-Grande ASP-Emergency group Source Type: research
[Translated article] Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol
CONCLUSION: Our study shows that CZP is effective in real clinical practice in patients with moderate-severe plaque PsO, with an improvement in absolute PASI and DLQI, as well as other scales, both for the total population and in the subgroups analysed. Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making.PMID:38148255 | DOI:10.1016/j.farma.2023.11.004 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 26, 2023 Category: Drugs & Pharmacology Authors: Andr és Navarro Ruiz Fernando Toledo Alberola Susana Aceituno Grupo ARCODERM Source Type: research
[Translated article] Design of a panel of indicators for antibiotic stewardship programs in the Emergency Department
CONCLUSIONS: The experts agreed on a panel of ASP Indicators adapted to the emergency services prioritised by level of relevance. This is as a helpful tool for the development of these programs and will contribute to monitoring the appropriateness of the use of antimicrobials in these units.PMID:38148256 | DOI:10.1016/j.farma.2023.11.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 26, 2023 Category: Drugs & Pharmacology Authors: Jes ús Ruiz-Ramos Mar ía Rosario Santolaya-Perrín Juan Gonz ález-Del-Castillo Francisco Javier Candel Alejandro Mart ín-Quirós Joaqu ín López-Contreras-González Agust ín Julián-Jiménez Ana Su árez-Lledó-Grande ASP-Emergency group Source Type: research
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:38114413 | DOI:10.1016/j.farma.2023.10.010 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 19, 2023 Category: Drugs & Pharmacology Authors: Ana Ganfornina Andrades Silvia F énix Caballero Alba Salguero Olid Emilio Jes ús Alegre Del-Rey Source Type: research
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:38114413 | DOI:10.1016/j.farma.2023.10.010 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 19, 2023 Category: Drugs & Pharmacology Authors: Ana Ganfornina Andrades Silvia F énix Caballero Alba Salguero Olid Emilio Jes ús Alegre Del-Rey Source Type: research
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:38114413 | DOI:10.1016/j.farma.2023.10.010 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 19, 2023 Category: Drugs & Pharmacology Authors: Ana Ganfornina Andrades Silvia F énix Caballero Alba Salguero Olid Emilio Jes ús Alegre Del-Rey Source Type: research
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:38114413 | DOI:10.1016/j.farma.2023.10.010 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 19, 2023 Category: Drugs & Pharmacology Authors: Ana Ganfornina Andrades Silvia F énix Caballero Alba Salguero Olid Emilio Jes ús Alegre Del-Rey Source Type: research
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:38114413 | DOI:10.1016/j.farma.2023.10.010 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 19, 2023 Category: Drugs & Pharmacology Authors: Ana Ganfornina Andrades Silvia F énix Caballero Alba Salguero Olid Emilio Jes ús Alegre Del-Rey Source Type: research
